TIDMAVCT
RNS Number : 7387O
Avacta Group PLC
05 October 2023
5 October 2023
Avacta Group plc
("Avacta" or the "Group" or the "Company")
Avacta to present promising new data from Affimer(R) and
pre|CISION(TM) platform assets at AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics
-- AVA3996: FAP-<ALPHA>-activated proteasome inhibitor
from pre|CISION(TM) platform concentrates proteasome inhibitor
payload in the tumour, increasing the therapeutic index of this
class of drugs
-- AVA032: anti-PD-L1 Affimer(R) fused to IL-15 demonstrates
encouraging in vitro and in vivo efficacy
Avacta Group plc (AIM: AVCT), a life sciences company focused on
improving healthcare outcomes through targeted cancer treatments
and diagnostics, today announces that it will be presenting two
posters at the AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics, taking place on 11-15 October 2023
in Boston Massachusetts.
Details of the poster presentations are as follows:
Abstract title: AVA3996, a novel pre|CISION(TM) medicine,
targets a warhead to the tumor microenvironment via Fibroblast
Activation Protein ("FAP") mediated cleavage to elicit tumor cell
kill
Poster number: C169
Session: Poster Session C
Session date and time: Saturday, October 14 | 12:30 pm-4:00 pm
Session location: Level 2, Exhibit Hall D
Abstract title: A novel, tumor-targeted immunocytokine
comprising an anti-PD-L1 Affimer(R) fused to IL-15 exhibits potent
anti-tumor activity
Poster number: A077
Session: Poster Session A
Session date and time: Thursday, October 12 | 12:30 pm-4:00 pm
Session location: Level 2, Exhibit Hall D
Dr Fiona McLaughlin, Chief Scientific Officer of Avacta
commented:
"We look forward to presenting the promising new data from
Avacta's Therapeutics platform assets at this conference. As
disclosed in the Company's announcement on 19 September 2023, our
lead asset AVA6000 continues to advance through the clinic at pace.
We are simultaneously conducting IND-enabling studies for promising
assets derived from the pre|CISION(TM) and Affimer(R) platforms.
The data to be presented showcases the potential of our two
therapeutic platforms to generate further high value clinical
assets.
"AVA3996, a FAP-<ALPHA>-activated proteasome inhibitor
based on our pre|CISION(TM) technology, demonstrates targeted
killing of cancer cells in vitro and, by concentrating the active
warhead in the tumour, reduces systemic toxicity associated with
this class of drug.
"AVA032, our anti-PD-L1 Affimer(R) fused to the pro-inflammatory
cytokine interleukin 15 (IL-15) displays encouraging efficacy when
tested in multiple models of immunomodulation, stimulating a potent
immune response and reversing the immunosuppressive tumour
microenvironment."
Further information regarding the conference can be found on the
ACCR's website here:
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/
The posters will be available to view following the conference
here: https://avacta.com/about/scientific-resources/
-Ends-
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 1904 21 7070
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications
Director
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0) 207 710 7600
and Broker) www.stifel.com
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / William
Palmer-Brown
Peel Hunt (Broker) Tel: +44 (0) 207 418 8900
James Steel / Chris Golden / Patrick www.peelhunt.com
Birkholm
ICR Consilium (Media and IR) avacta@consilium-comms.com
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company focused on improving
healthcare outcomes through targeted cancer treatments and
diagnostics.
Avacta has two divisions: an oncology biotech division
harnessing proprietary therapeutic platforms to develop novel,
highly targeted cancer drugs, and a diagnostics division, which is
executing on an M&A led growth strategy to create a
full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two
proprietary platforms, Affimer(R) and pre|CISION(TM) underpin its
cancer therapeutics whilst the diagnostics division leverages the
Affimer(R) platform to drive competitive advantage in its
markets.
The pre|CISION(TM) platform modifies chemotherapy to be
activated only in the tumour tissue, reducing systemic exposure and
toxicity. This is achieved by harnessing an enzyme called FAP which
is highly upregulated in most solid tumours compared with healthy
tissues, turning chemotherapy into a "precision medicine". The lead
pre|CISION(TM) programme, AVA6000 a tumour activated form of
doxorubicin, is in Phase 1 studies and has shown dramatic
improvement in safety compared with standard doxorubicin, and early
signs of clinical activity.
Affimer(R) is a novel biologic platform which has significant
technical and commercial advantages compared with antibodies and is
used both to develop advanced immunotherapies and to improve the
performance of immunodiagnostics.
With a balanced business and capital allocation model: a
high-value oncology pipeline supported by a revenue generating,
fast-growing diagnostics business, Avacta seeks to create long-term
shareholder value alongside patient benefit.
To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
About AVA3996
AVA3996 is a FAP- <ALPHA> -activated proteasome inhibitor,
based on the Company's pre|CISION(TM) technology platform. AVA3996
has the potential to become a targeted cancer treatment for various
indications, overcoming cytotoxicity issues displayed when the
free, non-targeted form of proteasome inhibitor is systemically
administered to patients.
About AVA032
AVA032 is an anti-PD-L1 Affimer(R) fused to the cytokine
interleukin 15 ("IL-15"). It carries improved properties compared
to monoclonal antibodies, currently used as cancer therapeutics,
and works to reverse the immunosuppressive tumour
micro-environment, inducing a lasting immune response aimed at
stimulating a patient's immune system to destroy cancer cells.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFSIFALEDSESS
(END) Dow Jones Newswires
October 05, 2023 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024